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Abstract
Background:  In Fabry disease (α-galactosidase A deficiency) accumulation of
Globotriaosylceramide (Gb3) leads to progressive organ failure and premature death. The
introduction of enzyme replacement therapy (ERT) was the beginning of a new era in this disorder,
and has prompted a broad range of research activities. This review aims to summarize recent
developments and progress with high impact for Fabry disease.
Methods: A Pubmed analysis was performed using the search terms "Fabry disease", "Anderson-
Fabry disease", "alpha-galactosidase A" and "Gb3". Of the given publications by 31st January 2009
only original articles recently published in peer reviewed journals were included for this review.
Case reports were included only when they comprised a new aspect. In addition we included
relevant conference abstracts when the results had not already been published as original articles.
Results: Apart from Gb3-accumulation cellular and organ specific damages may be related also to
inflammatory and immunological consequences. It will be interesting whether this may lead to new
therapeutic strategies in the treatment of Fabry disease. Since newborn screening is still difficult in
Fabry disease, detection of patients in populations at risk is of great importance. Undiagnosed
patients with Fabry disease may still be found in cohorts of subjects with renal diseases,
cardiomyopathy and TIA or stroke. Efforts should be undertaken to identify these individuals and
initialise ERT in order to hault disease progression. It has also been demonstrated that Gb3-
accumulation leads to pre-clinical damages and it is believed that early treatment may be the only
possibility so far to prevent irreversible organ damage.
Introduction
The introduction of enzyme replacement therapy (ERT)
for Fabry disease in 2001 was the beginning of a new era
for this lysosomal storage disorder. More than 2000
patients have been treated with either one of the two avail-
able formulations of genetically engineered α-galactosi-
dase A. In general, safety and efficacy of both, Agalsidase
alfa (Replagal, Shire Human Genetic Therapies) and Agal-
sidase beta (Fabrazyme, Genzyme Corp.), have been dem-
onstrated [1,2]. The introduction of these drugs was not
only the desired hope for patients. It broke also new
ground in research including a better understanding of
pathology, natural course of the disease, treatment and
outcome. Before the introduction of ERT for Fabry disease
it had already been known that the basis of this disorder
is the X-linked deficiency of the lysosomal enzyme α-
galactosidase A [3]. The accumulation of globotriaosylce-
ramide (Gb3) had been regarded as the key link between
pathology and clinical symptoms. Typical manifestations
had been described as angiokeratoma, sweating distur-
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bances, neuropathic pain, and hearing impairment. In
addition, affection of the heart, the kidney and the central
nervous system had been seen [4,5].
To keep up with newest research in such a developing field
is important, but may also be difficult. This review aims to
summarize recent developments in the understanding of
pathology, symptomatology, diagnosis, and treatment
effects in Fabry disease. A particular focus is brought on
publications appeared in 2008 as some of them are of out-
standing importance and high impact.
Methods
A Pubmed-research was undertaken by the end of January
2009 for publications covering all aspects of Fabry dis-
ease. Search terms were 'Fabry disease', 'Anderson-Fabry-
disease', 'alpha-galactosidase A', 'enzyme replacement
therapy', 'globotriaosylceramide', 'Gb3' and 'lysosomal
storage disease'. For this review, only recently published
original articles have been considered. Case reports were
included only if they described new findings. In addition
to this, we included available abstracts from international
conferences if the corresponding publications have not
yet been appeared in peer reviewed journals.
Results
Overall, 37 publications from different peer reviewed
journals and 9 conference abstracts were appraised for this
review. We classified these publications into eight catego-
ries focussing on (1) pathology, (2) heart, (3) neurology,
(4) kidney, (5) children with Fabry disease, (6) diagnosis,
(7) treatment, and (8) monitoring in Fabry disease.
Pathology
The absence of infantile manifestations of Fabry disease
despite deficient α-galactosidase A and Gb3-accumula-
tion supports the hypothesis that Gb3 is not solely
responsible for disease manifestation. However, Valbuena
et al. hypothesized that the overloading of lysosomes with
Gb3 may simply lead to the rupture of cytoplasma and in
consequence to cell death [6].
Secondary effects of Gb3 accumulation which might be
responsible for disease pathology include also inflamma-
tory processes [7]. Recently, Gb3 has been shown to be
identical with membranous CD77 [8] which is supposed
to play an important role in apoptosis and necrosis [9]. In
addition, Rozenfeld and co-workers reported perturbed
leukocyte function in Fabry disease compared to healthy
controls and abnormal numbers of different immune
cells, including lymphocytes, monocytes, CD8+ cells, B
cells and dendritic cells [10]. Noteworthy, in another
study no correlation was found between CRP-levels as a
global inflammatory marker and the Mainz-Severity-
Score-Index (MSSI) as a marker for disease severity [11].
Other authors reported on auto-immunological reactions
in α-galactosidase A deficiency. Moore et al. found higher
expressions of neuronal apoptosis inhibiting protein as a
key anti-apoptotic mediator in children with Fabry dis-
ease compared to healthy controls [12]. Noteworthy, this
upregulation did not change after institution of ERT,
whereas apoptosis inducing factor appears to be upregu-
lated under ERT. The authors were not able to explain
their observations, but further research has to be directed
on this topic.
Finally, Gb3-accumulation has been reported to induce
oxidative stress and/or the formation reactive oxygen spe-
cies (ROS) [13]. Lipids and proteins may be oxidised and
may be unable to function. Of note, ERT increased the
generation of ROS in vitro, and up-regulated the intracel-
lular adhesion molecule ICAM 1. The authors hypothe-
sized that ERT may enhance endothelial damage, allowing
to understand continuously occurring strokes in patients
on treatment.
Another gateway into alteration of endothelial function
may be given by the Nitric-Oxide-Synthase-3-genotypes.
Endothelium-derived nitric oxide is a key regulator of ves-
sel wall function and cardiovascular homeostasis. A
genetic variant of the Nitric-Oxide-Synthase-3-gene is sus-
pected to disturb this homeostasis and has been found to
be associated with a decreased thickness of the posterior
wall of the left ventricle [14]. This observation may in part
explain the large variability of cardiac phenotypes in Fabry
disease.
A so far unknown observation of Gb3-accumulation has
been made by Wang and colleagues who described Gb3
storage in pulmonary smooth muscle cells and vascular
endothelium of a female patient with Fabry disease [15].
This finding offers an explanation for dyspnoea in the
context of Fabry disease apart from cardiac involvement.
Four years of ERT in the 51-years old woman led to signif-
icant clinical improvement of pulmonary symptoms and
in part improved lung function. However, CT-scans con-
tinuously showed fibrotic alterations.
Heart
Despite the high frequency of cardiomyopathy in Fabry
disease [16], only little is known on the mechanisms lead-
ing to functional impairment and on the early cardiac
affection.
To identify early cardiac abnormalities Toro and col-
leagues performed Tissue Doppler Imaging (TDI)-studies
in 59 adult patients and compared these results with that
of 24 healthy controls [17]. The authors demonstrated sig-
nificant abnormalities of systolic and diastolic ventricular
function with TDI even in patients with normal conven-Orphanet Journal of Rare Diseases 2009, 4:21 http://www.ojrd.com/content/4/1/21
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tional echocardiography. In addition, isovolumetric con-
traction time was found to be the most sensitive
parameter for detecting these functional changes.
Consistent with this, Kampmann et al. reported on car-
diac manifestations of Fabry disease in 20 children below
the age of 18 years prior to ERT [18]. Thirty-five percent of
the children already had left ventricular hypertrophy, and
the remainder subjects had a LVM-index above the 75th
percentile of healthy controls. During the 26-months fol-
low-up period the LVM-index increased in more than 85%
of the patients, while the remainder patients entered the
echocardiographic criteria for LVH. Noteworthy, the
increase in LVM was not followed by abnormalities in
either systolic or diastolic function, and in general there
were no signs of LVH seen in ECG. Another warranting
observation of this study was the demonstration of
reduced heart rate variability (HRV) in boys with Fabry
disease suggestive of an impaired autonomic control of
the heart which may be responsible for the increased car-
diac morbidity. Palecek et al. demonstrated that also affec-
tion of the right ventricle is a common finding in both,
males and females with Fabry disease [19]. Impaired
diastolic function was observed in about 50% of the
patients, and the authors speculated that involvement of
both ventricles may reflect the progressive character of the
disease.
Weidemann et al. stressed the involvement of the heart
valves in particular in patients with advanced cardiomy-
opathy, where insufficiencies of the mitral, aortic and tri-
cuspid valve were found [20]. It is likely that the altered
myocardial morphology in advanced cardiomyopathy
maybe together with fibrosis of cardiomyocytes may indi-
rectly lead to heart valve regurgitation.
Apart from fibrosis of the myocytes, disturbances of the
myofilamental structure has been observed in isolated
cardiomyocytes of male patients with Fabry disease and
LVH [21]. A high percentage of Gb3 was found widely dis-
tributed over the cells, and it is not unlikely that the stor-
age material directly impairs ventricle function (e.g. by
impaired relaxation or stiffening of cardiomyocytes). The
authors hypothesised that such changes may be responsi-
ble for diastolic dysfunction in Fabry disease. On a more
functional level, Chimenti and co-workers found that the
maximal isometric tension of a single cardiomyocyte was
reduced [21]. This reduction correlated with the decreased
systolic velocities from TDI and with the degree of myofi-
brillolysis. In addition, myofibrillolysis was associated
with degradation of myofilamental proteins suggesting
that cardiomyocyte impairment may in part be explained
by proteolysis. Progression of Fabry disease cardiomyopa-
thy may be related to fibrosis of endomyocardial tissue,
but was not correlated with TDI measurements of systolic
or diastolic LV function in this study.
Cardiac involvement in Fabry disease is one of the major
causes for premature death in Fabry disease [4]. However,
it is generally accepted that classic myocardial infarction
as a result of atherosclerotic coronary heart disease is rare.
Coronary angiographic properties were determined by
intravascular ultrasound in nine patients and ten athero-
sclerotic controls [22]. Atherosclerotic plaques in Fabry
disease were suspected to have a larger number of lipid
cores, and the pattern of the lesions was more echogenic.
The authors speculated that Gb3 and disease-specific
trophic alterations may explain the differences to regular
atherosclerotic formations.
In a double-blind, randomized, placebo-controlled study
[23] sixteen adults were followed over a period of six
months before 10 of them entered a two years extension
study. The authors found a mean decrease in myocardial
Gb3-content of ~20% in the treated group whereas the
placebo-group showed a mean increase in Gb3 of ~10%
[23]. Though reduction of myocardial Gb3-content did
not reach significance, LVM as measured by cardiac MRI
and echocardiography was significantly decreased in the
patients treated with Agalsidase alfa compared to an
increase in the placebo group. After two years of treatment
these results were confirmed by repeated cardiac MRI.
Ejection fraction as a measure of cardiac function
remained normal or hypernormal in the entire cohort.
Shortening of QRS-duration confirmed previous reports
on normalized conduction [2]. The authors indicated that
the significant reduction in LVM may be clinically relevant
since LVM has been demonstrated to be an independent
risk factor for premature mortality in other conditions.
From an observational study it has been reported that ERT
with Agalsidase beta may reduce LVM and interventricular
septum thickness [24]. In contrast to this Koskenvuo et al.
reported only minimal effects of Agalsidase beta on car-
diac symptoms of nine patients with Fabry disease who
were enrolled in an open-lable study [25]. Only resting
heart rate was significantly decreased over a follow-up
period of 2 years, but no improvement in echocardio-
graphic measures, ECG or exercise capacity was observed.
Improvements seen in stroke volume on cardiac MRI after
12 months ERT were not retained after two years, and no
other parameter reached significance.
Echocardiographic follow-up over more than three years
in 29 males and females with Fabry disease under ERT
with either of the available Agalsidase formulations failed
to prove a decrease in left ventricular wall thickness, or left
atrial size though improvement of diastolic function was
observed [26]. However, it has to be noted that the age ofOrphanet Journal of Rare Diseases 2009, 4:21 http://www.ojrd.com/content/4/1/21
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the study population was relatively young (37 ± 12 years)
and that no further progression of the disease was
observed in respect to cardiac manifestations under ERT.
This observation is supported by a study from Kampmann
et al. on the natural course of cardiomyopathy in male
and female patients with Fabry disease [27]. Repeated
echocardiography was performed over an average time of
4.5 years in 76 patients. There, left ventricular mass index
increased with age in both, males and females, respec-
tively. Median time of onset of left ventricular hypertro-
phy was 44 years in males and 55 years in females. As
expected, LVH was more frequently found in male
patients and was also related to age. No functional meas-
ure was related to left ventricular mass index or left ven-
tricular hypertrophy. Of note, left ventricular mass index
increased by some 4 g/m2.7*year in men and slightly more
than 2 g/m2.7*year in women. Following the authors, this
difference may be explained by the mosaic-like distribu-
tion of Gb3 in female cardiomyocytes compared to male
patients. In summary, these studies recommend initiation
of ERT at an early stage of the disease since at least some
of the cardiac manifestations may be irreversible [26,27].
Recent data showed that left ventricular wall thickness
showed significant improvement over a period of eight
years in patients under ERT with Agalsidase alfa [28].
Apart from morphologic improvement of LVH and car-
diac mass, Lobo and co-workers tried to evaluate a clinical
effect of ERT on cardiac function by performing a 6-
minute-walk-test and bicycle stress testing [29]. However,
the authors mixed male and female patients despite the
different clinical affection. Moreover, females were on
ERT only one third of the time males were treated with
one of the enzyme formulations. In addition, both tests
used may be significantly biased, e.g. by motivation, neu-
ropathic pain in feet or aggravation of pain under physical
exercise.
Neurology
Probably the most debilitating symptom in Fabry disease
is neuropathic pain. Though often labelled as "acroparaes-
thesia", it is well known today that virtually the whole
body can become place of painful experiences [30].
The typical neurophysiologic pattern of pain in Fabry dis-
ease allows discrimination from other sensory neuropa-
thies. Standardized quantitative sensory testing
demonstrated severe impairment of thermal discrimina-
tion compared to patients with sensory neuropathies of
large nerve fibres and to patients with other small fibre
neuropathies [31].
Apart from the peripheral nervous system, the central
nervous system is also known to be affected in Fabry dis-
ease, too. Cerebrovascular events significantly contribute
to the pre-term mortality of Fabry disease with a median
cumulative survival time of 50 years [4]. Based on clinical-
neurological and MRI evaluation Buechner et al. reported
on a prevalence for CNS-involvement in up to 72% of
patients with Fabry disease [32]. Cerebrovascular disease
occurred at a mean age of 42 ± 11 years in males and
approximately 10 years later in females. In contrast to
other reports, the authors found a nearly equal distribu-
tion of cerebrovascular involvement between vertebro-
basilar and carotid districts.
Alari et al. observed changes in cerebral blood flow veloc-
ities (CBFV) in patients with Fabry disease who were
treated with ERT [33]. At baseline, there was a tendency
towards higher CBFV in patients with Fabry disease com-
pared to age-matched healthy controls. After 30 months
ERT CBFV decreased significantly, which is in good agree-
ment with previous observations over a shorter period of
time [34].
Neuropsychiatric symptoms in Fabry disease were evalu-
ated by Schermuly et al. together with MRI and diffusion
tensor imaging [35]. Patients with Fabry disease were sig-
nificantly more depressed and showed a lower cognitive
performance than healthy controls. Interestingly, pain
interference was significantly correlated to white matter
lesions supporting previous observations by Cole et al.
[36].
Kidney
Close examination and laboratory analyzes is important
to detect also pre-clinical affection of the kidney in Fabry
disease. Tøndel et al. [37] performed kidney biopsies in
nine children, including two boys under ERT. Accumula-
tion of Gb3 was found irregardless of clinical nephropa-
thy, and structural changes of the kidney were observed in
nearly 80% of the patients including glomerulosclerosis
and interstitial fibrosis already in these young patients.
Moreover, changes were seen in the glomerulum, the tub-
ulo-interstitial space and small renal vessels. Noteworthy,
the two boys receiving ERT developed de novo albuminu-
ria despite treatment. The authors suggested kidney biop-
sies in all children and adolescents with Fabry disease and
albuminuria in order to evaluate the extent of renal
damage.
Erroneously, for decades females with Fabry disease were
considered as carriers only. Meanwhile, there is no doubt
that they are in fact patients who may develop the whole
spectrum of the disease [5,38].
A cross-sectional analyzes of the Fabry Registry focussing
on kidney involvement in females revealed that renal
impairment occurs in all classes of the chronic kidney dis-Orphanet Journal of Rare Diseases 2009, 4:21 http://www.ojrd.com/content/4/1/21
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ease classification including end-stage renal disease [39].
Consistent with this other authors found proteinuria in
one third of the female and nearly two third of the male
patients, increasing with age in both genders. The latter
finding is in contrast to a previous report by Deegan et al.
[40], but was confirmed by other authors [6]. Kidney
affection was clearly evident by Gb3-accumulation in
every glomerular cell type, and accumulation in peritubu-
lar capillaries was grossly related to the severity of neph-
ropathy. These changes were observed in an early stage of
the disease, and the authors speculated on its value as an
indicator for ERT efficacy. In addition, non-specific
glomerular and tubulo-interstitial lesions of degenerative
origin were also seen. The authors concluded that kidney
involvement in females with Fabry disease is not different
from findings in male patients.
Rather seeking for morphologic but functional alterations
in patients with Fabry disease, Vylet'al and co-workers
reported on quantitative and qualitative changes in the
excretion of uromodelin (UMOD) [41]. Attenuated
UMOD-expression was suspected to be directly linked to
lysosomal storage processes as both, UMOD and accumu-
lated Gb3 meet in the Henle-Loop of the kidney. Deficient
UMOD-expression has been reported in association with
impaired tubular function, in particular with impaired
urine-concentration. Hence, the reported observations
may explain the changes in tubular function seen in Fabry
disease, and in particular the phenomenon of hyperfiltra-
tion reported in some patients.
Treatment effects have been analyzed based on data from
165 patients with Fabry disease enrolled in the Fabry Out-
come Survey [42]. Feriozzi et al. demonstrated that ERT
with Agalsidase alfa may slow the decline in renal func-
tion of male and female patients. Moreover, this effect was
also seen in patients with advanced renal failure (eGFR ≤
59 ml/min*1.73 m2), and it was sustained over a period
of three years.
Both, diagnosis and monitoring of kidney involvement in
Fabry disease is hindered by the repeated discrepancies
between estimated glomerular filtration rate (eGFR), 24-
hour urine creatinin clearance (Cr) and isotopic GFR
measurement.
Paediatric Fabry disease
An observational study on children enrolled in the Fabry
Registry characterized disease manifestation in 352 chil-
dren (194 boys, 158 girls) before the institution of ERT
[43]. In this cohort reported age at onset of symptoms was
6 years in boys and 9 years in girls, respectively. The most
frequent symptom was neuropathic pain which was
reported in about 60% of the boys and some 40% of the
girls. Gastrointestinal symptoms were frequently reported
with more than 1/4 of patients affected also on follow-up
(baseline definition not clear). The frequency of abnor-
mal skin findings (i.e. Angiokeratoma) in this group of
patients was about 25% for abnormal sweating, and
slightly more for abnormal heat tolerance. Abnormal cold
intolerance was documented in 10-18% of patients
(females vs. males). Cardiac involvement included
mainly cardiac valve dysfunction (~19% of patients) and
arrhythmias (~5% of patients). In addition, conduction
disturbances were also seen. Renal insufficiency was
reported in 3/144 patients with information on eGFR. The
increased frequency of hyperfiltration may be due to an
overestimation of eGFR in patients with chronic kidney
disease. However, it is also not unlikely that hyperfiltra-
tion is an early sign of kidney affection in the context of
Fabry disease. Of note, the information regarding quality
of life and pain assessment in this study have to be taken
with caution since both questionnaires (SF-36 and Brief
Pain Inventory) are validated for adults, but not for
children.
Diagnosis
Several studies on the natural history of Fabry disease as
well as analyses of the two available patient registries have
shown that diagnosis often is carried out more than a dec-
ade after onset of first symptoms [44,45]. Indeed, there
are patients with a diagnosis not before irreversible organ
damage has taken place. Several authors suggested early
institution of ERT in order to prevent irreversible organ
damage.
Projects are ongoing to evaluate the feasibility of newborn
screening for Fabry disease, and pilot studies have been
taken place in several countries [46,47]. Males may be eas-
ily detected by determination of α-galactosidase A from
dried blood spots, but there are still difficulties in detect-
ing females with this method. Determination of residual
enzyme activity in females may deliver erroneously nor-
mal activities in up to 40% of females with Fabry disease
despite significant clinical disease [48].
However, newborn screening for Fabry disease may once
be incorporated into already existing screening programs
using tandem-mass-spectrometry. Such an implementa-
tion would not only allow early diagnosis of Fabry dis-
ease, but may also provide valid information on the real
prevalence of Fabry disease.
This may be even more important since the pilot studies
in newborn screening as well as secondary screening of
populations at risk suggested a much higher prevalence
than previously reported [1,49]. In Austria screening of
male kidney transplant recipients revealed an incidence of
1:262 in this population [50], which is markedly higher
than previous studies on a similar cohort [51,52], but lessOrphanet Journal of Rare Diseases 2009, 4:21 http://www.ojrd.com/content/4/1/21
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than reported by Nakao et al. several years earlier in
patients undergoing haemodialysis [53]. Porsch et al.
detected two patients with deficient α-galactosidase A
activity out of 577 male patients with unknown reason for
renal failure and haemodialysis [54]. The authors agreed
that Fabry disease is still under-diagnosed also among
patients on dialysis, and they emphasized the importance
of proper medical work-up in patients with end-stage
renal disease or renal failure.
General considerations regarding ERT
Providing the missing enzyme to patients with Fabry dis-
ease sounds easy and in fact is simple to perform. Con-
firming previous reports, Keslová-Veselíková et al.
reported that intravenously administered enzyme reaches
the lysosome via Mannose-6-phosphate-receptor medi-
ated uptake [55]. The uptake of Agalsidase beta into the
cells was higher than in Agalsidase alfa, a fact attributed to
the enrichment with mannose moieties in Agalsidase
beta. In both enzymes a total clearance of the fibroblastic
lysosomes from Gb3 was observed after 24 h, and total
quantitative analyzes of this clearance revealed a dose-
dependency. However, the consumption of Agalsidase
beta within the fibroblasts was much faster compared to
Agalsidase alfa. The different pattern of enzyme consump-
tion in different cell types and tissues support the idea of
early treatment in Fabry disease in order to prevent func-
tional organ damage. Noteworthy, uptake of Agalsidase
into endothelial cells was better compared to uptake e.g.
into cardiocytes and perineural cells. Hence, for some tis-
sues it may be more effective to prevent Gb3 accumula-
tion rather than cleave the storage material after years.
Such a preventive effect may be needed in particular in
cells after mitosis and cells with low potential for regener-
ation, e.g. myocardial cells. However, clinical studies on
these effects are lacking.
Though several authors suggested early treatment of
patients with Fabry disease using ERT, no randomized
double-blind placebo-controlled studies have been per-
formed in children, and most information in the paediat-
ric age group results from observations based on the two
clinical surveillance programmes. Anyhow, Ries et al. have
evaluated the pharmacokinetic profile of Agalsidase alfa
and have shown that this is comparable with that in adult
patients [56]. Moreover, Wraith et al. evaluated safety and
efficacy of Agalsidase beta in children aging 8-15 years in
an open-label study [57]. There, ERT resulted in a decrease
of Gb3-accumulation in skin biopsies and improvement
of gastrointestinal symptoms after 24 weeks treatment.
Interestingly, the authors did not find renal or cardiac
symptoms at baseline, and stabilisation was reported
under ERT. Forty percent of the patients experienced infu-
sion associated reactions, and nearly 70% of patients
developed IgG-antibodies.
Vedder et al. found that α-galactosidase-A-antibodies in
adults occurred in about every third patient, but twice as
often in Agalsidase beta compared to Agalsidase alfa [58].
Confirming previous observations and in agreement with
current understanding of pathology in females, no female
patient developed antibodies. Of the patients with neu-
tralizing antibodies more than 75% were treated with
Agalsidase beta, and the authors found a correlation
between antibody formation and dosage, but no correla-
tion between antibodies and residual enzyme activity/
GLA-mutation. In contrast to previous reports [2,59] and
independent from the administered enzyme, no decline
of antibody levels was observed after 24 months. Clinical
parameters such as renal function did not change over a
follow-up period of 12 months in any of the treatment
groups, and were not related to antibody formation. A
decrease in LVM was reported only for 1.0 mg/kg Agalsi-
dase beta, however, the combination of patients who
received 0.2 mg/kg Agalsidase beta with those receiving
0.2 mg/kg Agalsidase alfa may be unfortunate as both
drugs are different from each other [60]. The authors con-
cluded that high dose treatment may be more effective in
reducing Gb3-levels, however, following treatment failure
seven patients in this cohort received increased dosages of
Agalsidase during the study, and five of them developed
worsening of ischemic lesions in the CNS. Hence, a higher
dosage may overcome antibody formation, but may not
necessarily lead to clinical improvement. In addition, the
authors stated that a translation to clinical efficacy is diffi-
cult to make as there are no reports available on the clini-
cal outcome of patients with Fabry disease receiving
enzyme replacement therapy in relation to antibody
formation.
Apart from ERT there is another treatment strategy cur-
rently under investigation that is chaperone therapy.
Chaperones are able to increase the residual activity in
affected individuals, and as they are small molecules they
are supposed to cross the blood brain barrier. Shin et al.
reported on an association between genotype and
response to chaperone therapy [61], a fact that may not
surprise. The effect of chaperone therapy is, e.g. to correct
the structure of misfolded proteins which in their faulty
configuration may not be effective. Hence, only those
patients with misfolded enzyme products as a conse-
quence of GLA-mutations may benefit from chaperone
treatment.
Monitoring
Both, the pattern of clinical symptoms as well as the
response to ERT is heterogeneous and not foreseeable. A
biomarker that is uniformly found throughout male and
female patients representing the total load of Gb3-storage
throughout the body would be very helpful. Ideally, suchOrphanet Journal of Rare Diseases 2009, 4:21 http://www.ojrd.com/content/4/1/21
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a biomarker should allow also diagnosing patients inde-
pendent of their gender.
In this context, Aerts and co-workers reported on the
occurrence of lyso-Gb3 in plasma of patients with Fabry
disease [62]. Lyso-Gb3 is structurally similar to Gb3
which could not be identified in plasma from control
individuals. In hemizygotes a strong correlation between
plasma Gb3 and lyso-Gb3 was found, but there was no
correlation observed between lyso-Gb3 and the Mainz-
Severity-Score-Index as a clinical index for disease severity
in male patients. The latter finding may not necessarily
limit the impact of lyso-Gb3 but may be related to meth-
odological concerns regarding the MSSI as a cross-section-
ally used severity score. However, the MSSI has recently
been shown to correlate in a more longitudinal setting
with changes under ERT [63]. Lyso-Gb3 in females corre-
lated with the MSSI and with left ventricular mass. In a cell
culture, lyso-Gb3 promoted proliferation of smooth mus-
cle cells when given in concentrations similar to those
found in plasma of symptomatic patients with Fabry dis-
ease. In contrast to Gb3, lyso-Gb3 influenced vascular
remodelling in vivo, and ERT with either form of Agalsi-
dase lead to decreased concentrations of lyso-Gb3 over a
period of one year, but not to complete absence of the
compound. In summary, lyso-Gb3 cannot be used as a
biomarker.
Another approach for a biomarker was presented by Tho-
maidis and co-workers, who suggested membranous
CD77, the membranous form of Gb3 [8]. The amount of
membranous CD77 shall mirror the tissue load of Gb3,
and it has been shown to decrease under ERT with Agalsi-
dase alfa in a kidney cell model. Since CD77 may play an
important role in apoptosis and necrosis [9], there may be
a link to kidney failure in patients with Fabry disease and
accumulation of Gb3.
Conclusion
Important progress has been made regarding the under-
standing of disease pathology, diagnosis and treatment
effects in Fabry disease. Obviously, Gb3-accumulation
alone is not responsible for the cellular and organ specific
consequences. In fact, inflammation and immunological
aspects have to be considered in the development of Fabry
disease, too. It remains open whether or not these find-
ings may lead to future treatment options.
Selective screening of populations at risk have clearly
shown that there are still undiagnosed patients with Fabry
disease, and efforts should be undertaken to identify these
individuals, e.g. in cohorts of patients with cardiomyopa-
thy, unexplained renal disease and/or populations with
stroke. This is even more important since there is good
evidence that ERT may at least halt progression of Fabry
disease. Moreover, the publications reviewed here dem-
onstrate pre-clinical damages of heart, kidney and CNS. If
there is, however, the possibility that ERT in Fabry disease
may prevent irreversible organ damage as it is suggested
by some authors and believed by experts in this field,
treatment has to be started in young age.
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